• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • NMPA Provides Evaluation Guidance on Material Changes for Passive Medical Devices

NMPA Provides Evaluation Guidance on Material Changes for Passive Medical Devices

raw material change passive medical device
Wednesday, 03 June 2020 / Published in Medical Device

NMPA Provides Evaluation Guidance on Material Changes for Passive Medical Devices

On 19.05.2020, the NMPA (National Medical Products Administration) addressed the guidance notes (No.33-2020) for NMPA Legal Agents to formulate risk control measures due to the changes in raw materials used for manufacturing passive medical devices. With this guidance, NMPA Legal Agents should be in a better position to determine if it is necessary to apply for registration approval for the changes.

According to the guidance notes, the NMPA Legal Agent is responsible to evaluate and determine if the raw material changes would initiate any biological hazards, as well as consider whether there will be an impact to the chemical properties and physical performance of the parts or the medical device itself.

The common changes in the raw materials include, but are not limited to the following:

  • Change of the type;
  • Change of the composition and ratio; and
  • Change of the preparation process.

The NMPA Legal Agent should always formulate an effective risk control plan and evaluate the effectiveness of the risk control measures. After taking risk control measures, any remaining risks should be evaluated using the criteria as specified in the risk management plan. If the residual risk is considered to be unacceptable, further risk control measures or risk-benefit analysis should be taken until the raw material has been accepted or rejected.

This guidance document does not act as an enforced regulation, and does not stipulate whether registration review and approval is required for material changes.

By Jacky Li. Contact Cisema to learn more.

Tagged under: medical device raw materials, passive medical devices, raw material change

What you can read next

NMPA: Funding for Testing of Medical Devices
CMDE Preps for AI Software to Soar in China
Recalls of Medical Device Regulation Updated

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.